More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.

Tomas Jelinek Renata Bezděková David Zihala Tereza Ševčíková Anjana Anilkumar SitharaLenka PospisilovaSabina SevcikovaPetra PolackovaMartin StorkZdenka KnechtovaOndrej Venglar Veronika Kapustová Tereza PopkovaLudmila MuronovaZuzana Chyra Matous Hrdinka Michal Simicek Juan-José Garcés Noemi Puig María-Teresa CedenaArtur JurczyszynJorge J CastilloMiroslav PenkaJakub Radocha Maria-Victoria Mateos-Manteca Jesús San F Miguel Juan José Lahuerta Ludek Pour Lucie Říhová Roman Hájek

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Our study uncovers that ≥ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

Keyphrases

circulating tumor cells
circulating tumor
flow cytometry
multiple myeloma
induced apoptosis
single cell
bone marrow
acute myeloid leukemia
cell cycle arrest
cell therapy
cell free
stem cells
mesenchymal stem cells